The University of Southampton
University of Southampton Institutional Repository

Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results

Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results
Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results
AIMS: A variety of antithrombotic regimens have been described for the early postoperative period after bioprosthetic aortic valve replacement (AVR). This study reviews antithrombotic practice for patients undergoing bioprosthetic AVR with or without coronary artery bypass graft (CABG) amongst the centers participating in the ACTION (Anticoagulation Treatment Influence on Postoperative Patients) Registry. METHODS AND RESULTS: An antithrombotic therapy questionnaire was answered by the 49 centers participating in the ACTION Registry located in Europe, Middle East, Canada and Asia. The 43% of centers prescribe vitamin K antagonist (VKA), 20% prescribe VKA and acetyl salicylic acid (ASA), 33% prescribe only ASA and 4% do not prescribe any therapy after bioprosthetic AVR. For patients undergoing bioprosthetic AVR and CABG 39% of the centers prescribe VKA and ASA, 37% prescribe VKA and 24% prescribe ASA. After the first three postoperative months following bioprosthetic AVR, 61% of the centers prescribe only ASA, while 39% do not prescribe any therapy. Patients with bioprosthetic AVR and CABG receive ASA in 90% centers, in 2% centers VKA and ASA, and 8% centers do not prescribe any antithrombotic. CONCLUSION: This study demonstrates that, despite guidelines published by several professional societies, medical practice for the prevention of thrombotic events early after bioprosthetic AVR varies widely among cardiac surgical centers
review, research, acid, coronary artery bypass, methods, aortic valve, cardiovascular, therapy, surgery, europe, societies
1010-7940
531-536
Colli, A.
e01622d0-c197-4266-b11c-88ee2a42cd4f
Verhoye, J.P.
fc5f8f06-5c13-458a-80ab-0bf94ae84b6f
Heijmen, R.
9a0662cf-9db7-4282-a803-904d871db09d
Strauch, J.T.
7bbac7f6-9ad0-49ad-8802-392fec25e715
Hyde, J.A.
a07e42a2-1c01-4430-80de-c56932bbaf17
Pagano, D.
28da09f4-abb3-45c2-a201-37fdb60f1ced
Antunes, M.
cedc822d-07d3-4e7f-98cf-60228435b99f
Koertke, H.
5ca7a8a0-2902-4818-987f-a380e17006e6
Ohri, S.K.
8aa5698c-78cf-4f59-a5af-5afa46f0348c
Bail, D.H.
3f798540-b5b7-43a4-96e7-cd5f11721926
Leprince, P.
6580909c-f647-4ffb-adbf-b97ac2d33cb7
Van Straten, B.H.
6cf59651-8231-4f9d-bc2d-f0e1264cc22f
Gherli, T.
8f17c614-9dcf-477c-aea0-6eb13ce4ae40
Colli, A.
e01622d0-c197-4266-b11c-88ee2a42cd4f
Verhoye, J.P.
fc5f8f06-5c13-458a-80ab-0bf94ae84b6f
Heijmen, R.
9a0662cf-9db7-4282-a803-904d871db09d
Strauch, J.T.
7bbac7f6-9ad0-49ad-8802-392fec25e715
Hyde, J.A.
a07e42a2-1c01-4430-80de-c56932bbaf17
Pagano, D.
28da09f4-abb3-45c2-a201-37fdb60f1ced
Antunes, M.
cedc822d-07d3-4e7f-98cf-60228435b99f
Koertke, H.
5ca7a8a0-2902-4818-987f-a380e17006e6
Ohri, S.K.
8aa5698c-78cf-4f59-a5af-5afa46f0348c
Bail, D.H.
3f798540-b5b7-43a4-96e7-cd5f11721926
Leprince, P.
6580909c-f647-4ffb-adbf-b97ac2d33cb7
Van Straten, B.H.
6cf59651-8231-4f9d-bc2d-f0e1264cc22f
Gherli, T.
8f17c614-9dcf-477c-aea0-6eb13ce4ae40

Colli, A., Verhoye, J.P., Heijmen, R., Strauch, J.T., Hyde, J.A., Pagano, D., Antunes, M., Koertke, H., Ohri, S.K., Bail, D.H., Leprince, P., Van Straten, B.H. and Gherli, T. (2008) Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. European Journal of Cardio-thoracic Surgery, 33 (4), 531-536. (doi:10.1016/j.ejcts.2007.12.019).

Record type: Article

Abstract

AIMS: A variety of antithrombotic regimens have been described for the early postoperative period after bioprosthetic aortic valve replacement (AVR). This study reviews antithrombotic practice for patients undergoing bioprosthetic AVR with or without coronary artery bypass graft (CABG) amongst the centers participating in the ACTION (Anticoagulation Treatment Influence on Postoperative Patients) Registry. METHODS AND RESULTS: An antithrombotic therapy questionnaire was answered by the 49 centers participating in the ACTION Registry located in Europe, Middle East, Canada and Asia. The 43% of centers prescribe vitamin K antagonist (VKA), 20% prescribe VKA and acetyl salicylic acid (ASA), 33% prescribe only ASA and 4% do not prescribe any therapy after bioprosthetic AVR. For patients undergoing bioprosthetic AVR and CABG 39% of the centers prescribe VKA and ASA, 37% prescribe VKA and 24% prescribe ASA. After the first three postoperative months following bioprosthetic AVR, 61% of the centers prescribe only ASA, while 39% do not prescribe any therapy. Patients with bioprosthetic AVR and CABG receive ASA in 90% centers, in 2% centers VKA and ASA, and 8% centers do not prescribe any antithrombotic. CONCLUSION: This study demonstrates that, despite guidelines published by several professional societies, medical practice for the prevention of thrombotic events early after bioprosthetic AVR varies widely among cardiac surgical centers

This record has no associated files available for download.

More information

Published date: 2008
Keywords: review, research, acid, coronary artery bypass, methods, aortic valve, cardiovascular, therapy, surgery, europe, societies

Identifiers

Local EPrints ID: 61009
URI: http://eprints.soton.ac.uk/id/eprint/61009
ISSN: 1010-7940
PURE UUID: 33736e52-2adb-4461-a98d-a54bea1e4090

Catalogue record

Date deposited: 11 Sep 2008
Last modified: 16 Jul 2024 17:13

Export record

Altmetrics

Contributors

Author: A. Colli
Author: J.P. Verhoye
Author: R. Heijmen
Author: J.T. Strauch
Author: J.A. Hyde
Author: D. Pagano
Author: M. Antunes
Author: H. Koertke
Author: S.K. Ohri
Author: D.H. Bail
Author: P. Leprince
Author: B.H. Van Straten
Author: T. Gherli

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×